ANIK vs SI
ANIK: Anika Therapeutics manufactures and markets hyaluronic acid (HA)-based medical products for orthopedic pain management, tissue regeneration, and non-orthopedic surgical applications. SI: Shoulder Innovations develops orthopedic devices for shoulder and upper extremity conditions, showing explosive revenue growth but facing profitability challenges and dramatic stock depreciation.
Side-by-side fundamentals
| Metric | ANIK | SI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.01 | $20.31 | |
| Market cap as of 2026-07-23 | $199M | $421M | |
| PEG as of 2026-07-23 | n/a | -0.06 | |
| Net margin as of 2026-07-23 | -9.5% | -17.1% | ANIK higher |
| Gross margin as of 2026-07-23 | +58.6% | +77.0% | SI higher |
| Operating margin as of 2026-07-23 | -10.5% | -55.4% | ANIK higher |
| ROE as of 2026-07-23 | -7.7% | -13.6% | ANIK higher |
| ROA as of 2026-07-23 | -5.9% | -10.9% | ANIK higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.11 | ANIK lower |
| Revenue growth (YoY) as of 2026-07-23 | -15.4% | +151.0% | SI higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | n/a | |
| Beta as of 2026-07-23 | 0.22 | 14.87 | |
| 1-year return as of 2026-07-22 close | +41.8% | -98.9% | ANIK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.